Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis

The Lancet Infectious Diseases

Volumn 18, Issue 1, 2018, Pages 95-107

  Schuetz, Philipp ^a,b   Wirz, Yannick ^a   Sager, Ramon ^a   Christ Crain, Mirjam ^b,c   Stolz, Daiana ^b,c   Tamm, Michael ^b,c   Bouadma, Lila ^e   Luyt, Charles E ^f   Wolff, Michel ^e   Chastre, Jean ^f   Tubach, Florence ^g   Kristoffersen, Kristina B ^h   Burkhardt, Olaf ⁱ   Welte, Tobias ⁱ   Schroeder, Stefan ^j   Nobre, Vandack ^k   Wei, Long ^l   Bucher, Heiner C ^b,d   Annane, Djillali ^m   Reinhart, Konrad ⁿ   Falsey, Ann R ^o   Branche, Angela ^o   Damas, Pierre ^p   Nijsten, Maarten ^q   de Lange, Dylan W ^r   Deliberato, Rodrigo O ^s   Oliveira, Carolina F ^k   Maravić Stojković, Vera ^t   Verduri, Alessia ^u   Beghé, Bianca ^u   Cao, Bin ^v   Shehabi, Yahya ^w,x   Jensen, Jens Ulrik S ^y   Corti, Caspar ^z   van Oers, Jos A H ^aa   Beishuizen, Albertus ^ab   Girbes, Armand R J ^ac   de Jong, Evelien ^ac   Briel, Matthias ^b,d,ad   Mueller, Beat ^a,b   more..

^a CANTONAL HOSPITAL AARAU   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f SORBONNE UNIVERSITÉ   (France)

^g ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^h AARHUS UNIVERSITY HOSPITAL   (Denmark)

ⁱ HANNOVER MEDICAL SCHOOL   (Germany)

^j Department of Anesthesiology and Intensive Care Medicine   (Germany)

^k FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^l SHANGHAI JIAO TONG UNIVERSITY   (China)

^m UNIVERSITÉ PARIS SACLAY   (France)

ⁿ JENA UNIVERSITY HOSPITAL   (Germany)

^o UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^p UNIVERSITY OF LIÈGE   (Belgium)

^q UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^r UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^s HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^t Cardiovascular Institute Dedinje   (Serbia)

^u UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^v CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^w SOUTHERN HEALTH   (Australia)

^x MONASH UNIVERSITY   (Australia)

^y UNIVERSITY OF COPENHAGEN   (Denmark)

^z BISPEBJERG HOSPITAL   (Denmark)

^aa CPRLab   (Netherlands)

^ab MEDISCH SPECTRUM TWENTE   (Netherlands)

^ac VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^ad MCMASTER UNIVERSITY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; PROCALCITONIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; ARTICLE; BRONCHITIS; DRUG EFFECT; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG USE; HUMAN; LENGTH OF STAY; META ANALYSIS; MORTALITY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; ADULT; ADVERSE DRUG REACTION; AGED; BACTERIAL INFECTION; BLOOD; FEMALE; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; PROCALCITONIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY TRACT INFECTIONS; SURVIVAL ANALYSIS;

EID: 85031330655     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(17)30592-3     Document Type: Article

References (63)

1. US Food and Drug Administration. FDA press release. FDA clears test to help manage antibiotic treatment for lower respiratory tract infections and sepsis. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm543160.htm, Feb 23, 2017 (accessed Oct 2, 2017).
2. Schuetz, P, Albrich, W, Mueller, B, Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Med, 9, 2011, 107.
3. Schuetz, P, Christ-Crain, M, Muller, B, Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections—hope for hype?. Swiss Med Wkly 139 (2009), 318–326.
4. Charles, PE, Tinel, C, Barbar, S, et al. Procalcitonin kinetics within the first days of sepsis: relationship with the appropriateness of antibiotic therapy and the outcome. Crit Care, 13, 2009, R38.
5. Sager, R, Kutz, A, Mueller, B, Schuetz, P, Procalcitonin-guided diagnosis and antibiotic stewardship revisited. BMC Med, 15, 2017, 15.
6. Musher, DM, Thorner, AR, Community-acquired pneumonia. N Engl J Med 371 (2014), 1619–1628.
7. Silverman, M, Povitz, M, Sontrop, JM, et al. Antibiotic prescribing for nonbacterial acute upper respiratory infections in elderly persons. Ann Intern Med 166 (2017), 765–774.
8. Schuetz, P, Albrich, W, Christ-Crain, M, Chastre, J, Mueller, B, Procalcitonin for guidance of antibiotic therapy. Expert Rev Anti Infect Ther 8 (2010), 575–587.
9. de Jong, E, van Oers, JA, Beishuizen, A, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis 16 (2016), 819–827.
10. Schuetz, P, Chiappa, V, Briel, M, Greenwald, JL, Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med 171 (2011), 1322–1331.
11. Wu, MH, Lin, CC, Huang, SL, et al. Can procalcitonin tests aid in identifying bacterial infections associated with influenza pneumonia? A systematic review and meta-analysis. Influenza Other Respir Viruses 7 (2012), 349–355.
12. Berg, P, Lindhardt, BO, The role of procalcitonin in adult patients with community-acquired pneumonia—a systematic review. Dan Med J, 59, 2012, A4357.
13. Bloos, F, Trips, E, Nierhaus, A, et al. Effect of sodium selenite administration and procalcitonin-guided therapy on mortality in patients with severe sepsis or septic shock: a randomized clinical trial. JAMA Intern Med 176 (2016), 1266–1276.
14. Bouadma, L, Luyt, CE, Tubach, F, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 375 (2010), 463–474.
15. Branche, AR, Walsh, EE, Vargas, R, et al. Serum procalcitonin measurement and viral testing to guide antibiotic use for respiratory infections in hospitalized adults: a randomized controlled trial. J Infect Dis 212 (2015), 1692–1700.
16. Briel, M, Schuetz, P, Mueller, B, et al. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med 168 (2008), 2000–2007.
17. Burkhardt, O, Ewig, S, Haagen, U, et al. Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection. Eur Respir J 36 (2010), 601–607.
18. Christ-Crain, M, Jaccard-Stolz, D, Bingisser, R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 363 (2004), 600–607.
19. Christ-Crain, M, Stolz, D, Bingisser, R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 174 (2006), 84–93.
20. Corti, C, Fally, M, Fabricius-Bjerre, A, et al. Point-of-care procalcitonin test to reduce antibiotic exposure in patients hospitalized with acute exacerbation of COPD. Int J Chron Obstruct Pulmon Dis 11 (2016), 1381–1389.
21. Deliberato, RO, Marra, AR, Sanches, PR, et al. Clinical and economic impact of procalcitonin to shorten antimicrobial therapy in septic patients with proven bacterial infection in an intensive care setting. Diagn Microbiol Infect Dis 76 (2013), 266–271.
22. Hochreiter, M, Kohler, T, Schweiger, AM, et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Crit Care, 13, 2009, R83.
23. Kristoffersen, KB, Sogaard, OS, Wejse, C, et al. Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admission—a randomized trial. Clin Microbiol Infect 15 (2009), 481–487.
24. Layios, N, Lambermont, B, Canivet, JL, et al. Procalcitonin usefulness for the initiation of antibiotic treatment in intensive care unit patients. Crit Care Med 40 (2012), 2304–2309.
25. Long, W, Deng, X, Zhang, Y, Lu, G, Xie, J, Tang, J, Procalcitonin guidance for reduction of antibiotic use in low-risk outpatients with community-acquired pneumonia. Respirology 16 (2011), 819–824.
26. Long, W, Deng, XQ, Tang, JG, et al. The value of serum procalcitonin in treatment of community acquired pneumonia in outpatient. Chin J Intern Med 48 (2009), 216–219 (in Chinese).
27. Long, W, Li, LJ, Huang, GZ, et al. Procalcitonin guidance for reduction of antibiotic use in patients hospitalized with severe acute exacerbations of asthma: a randomized controlled study with 12-month follow-up. Crit Care, 18, 2014, 471.
28. Maravić-Stojković, V, Lausević-Vuk, L, Jović, M, Ranković, A, Borzanović, M, Marinković, J, Procalcitonin-based therapeutic strategy to reduce antibiotic use in patients after cardiac surgery: a randomized controlled trial. Srp Arh Celok Lek 139 (2011), 736–742.
29. Nobre, V, Harbarth, S, Graf, JD, Rohner, P, Pugin, J, Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 177 (2008), 498–505.
30. Oliveira, CF, Botoni, FA, Oliveira, CR, et al. Procalcitonin versus C-reactive protein for guiding antibiotic therapy in sepsis: a randomized trial. Crit Care Med 41 (2013), 2336–2343.
31. Schroeder, S, Hochreiter, M, Koehler, T, et al. Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbecks Arch Surg 394 (2009), 221–226.
32. Schuetz, P, Christ-Crain, M, Thomann, R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 302 (2009), 1059–1066.
33. Shehabi, Y, Sterba, M, Garrett, PM, et al. Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial. Am J Respir Crit Care Med 190 (2014), 1102–1110.
34. Stolz, D, Christ-Crain, M, Bingisser, R, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 131 (2007), 9–19.
35. Stolz, D, Smyrnios, N, Eggimann, P, et al. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Respir J 34 (2009), 1364–1375.
36. Verduri, A, Luppi, F, D'Amico, R, et al. Antibiotic treatment of severe exacerbations of chronic obstructive pulmonary disease with procalcitonin: a randomized noninferiority trial. PLoS One, 10, 2015, e0118241.
37. Wang, JX, Zhang, SM, Li, XH, Zhang, Y, Xu, ZY, Cao, B, Acute exacerbations of chronic obstructive pulmonary disease with low serum procalcitonin values do not benefit from antibiotic treatment: a prospective randomized controlled trial. Int J Infect Dis 48 (2016), 40–45.
38. Schuetz, P, Briel, M, Christ-Crain, M, et al. Procalcitonin to initiate or withhold antibiotics in acute respiratory tract infections (protocol). Cochrane Database Syst Rev, 4, 2008 CD007498.
39. Schuetz, P, Muller, B, Christ-Crain, M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev, 9, 2012 CD007498.
40. Stewart, LA, Clarke, M, Rovers, M, et al. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA 313 (2015), 1657–1665.
41. Liberati, A, Altman, DG, Tetzlaff, J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62 (2009), e1–e34.
42. Guyatt, GH, Oxman, AD, Vist, GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336 (2008), 924–926.
43. Thompson, SG, Turner, RM, Warn, DE, Multilevel models for meta-analysis, and their application to absolute risk differences. Stat Methods Med Res 10 (2001), 375–392.
44. Turner, RM, Omar, RZ, Yang, M, Goldstein, H, Thompson, SG, A multilevel model framework for meta-analysis of clinical trials with binary outcomes. Stat Med 19 (2000), 3417–3432.
45. Higgins, JP, Thompson, SG, Deeks, JJ, Altman, DG, Measuring inconsistency in meta-analyses. BMJ 327 (2003), 557–560.
46. Mizgerd, JP, Acute lower respiratory tract infection. N Engl J Med 358 (2008), 716–727.
47. Gonzales, R, Steiner, JF, Sande, MA, Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA 278 (1997), 901–904.
48. Lawrence, KL, Kollef, MH, Antimicrobial stewardship in the intensive care unit: advances and obstacles. Am J Respir Crit Care Med 179 (2009), 434–438.
49. Kutz, A, Briel, M, Christ-Crain, M, et al. Prognostic value of procalcitonin in respiratory tract infections across clinical settings. Crit Care, 19, 2015, 74.
50. Schuetz, P, Hausfater, P, Amin, D, et al. Biomarkers from distinct biological pathways improve early risk stratification in medical emergency patients: the multinational, prospective, observational TRIAGE study. Crit Care, 19, 2015, 377.
51. Linscheid, P, Seboek, D, Schaer, DJ, Zulewski, H, Keller, U, Muller, B, Expression and secretion of procalcitonin and calcitonin gene-related peptide by adherent monocytes and by macrophage-activated adipocytes. Crit Care Med 32 (2004), 1715–1721.
52. Christ-Crain, M, Muller, B, Procalcitonin in bacterial infections—hype, hope, more or less?. Swiss Med Wkly 135 (2005), 451–460.
53. Christ-Crain, M, Muller, B, Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J 30 (2007), 556–573.
54. Linscheid, P, Seboek, D, Zulewski, H, Keller, U, Muller, B, Autocrine/paracrine role of inflammation-mediated calcitonin gene-related peptide and adrenomedullin expression in human adipose tissue. Endocrinology 146 (2005), 2699–2708.
55. Wacker, C, Prkno, A, Brunkhorst, FM, Schlattmann, P, Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis 13 (2013), 426–435.
56. Muller, F, Christ-Crain, M, Bregenzer, T, et al. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest 138 (2010), 121–129.
57. Schuetz, P, Birkhahn, R, Sherwin, R, et al. Serial procalcitonin predicts mortality in severe sepsis patients: results from the Multicenter Procalcitonin MOnitoring SEpsis (MOSES) Study. Crit Care Med 45 (2017), 781–789.
58. Roberts, RR, Hota, B, Ahmad, I, et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis 49 (2009), 1175–1184.
59. Classen, DC, Jaser, L, Budnitz, DS, Adverse drug events among hospitalized Medicare patients: epidemiology and national estimates from a new approach to surveillance. Jt Comm J Qual Patient Saf 36 (2010), 12–21.
60. Garnacho-Montero, J, Gutierrez-Pizarraya, A, Escoresca-Ortega, A, et al. De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med 40 (2014), 32–40.
61. Schuetz, P, Mueller, B, Biomarker-guided de-escalation of empirical therapy is associated with lower risk for adverse outcomes. Intensive Care Med, 40, 2014, 141.
62. Meili, M, Kutz, A, Briel, M, et al. Infection biomarkers in primary care patients with acute respiratory tract infections-comparison of procalcitonin and C-reactive protein. BMC Pulm Med, 16, 2016, 43.
63. Meili, M, Muller, B, Kulkarni, P, Schutz, P, Management of patients with respiratory infections in primary care: procalcitonin, C-reactive protein or both?. Expert Rev Respir Med 9 (2015), 587–601.